Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1

Journal of Medicinal Chemistry

Volumn 60, Issue 3, 2017, Pages 1089-1104

  Khurana, Leepakshi ^a   Fu, Bo Qiao ^b   Duddupudi, Anantha L ^b   Liao, Yu Hsien ^a   Immadi, Sri Sujana ^b   Kendall, Debra A ^a   Lu, Dai ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CYANOPHENYL) 3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 ACETYLPHENYL) 3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 BROMOPHENYL) 3 [3 [2 (PYRROLIDIN 1 YL)PYRIMIDIN 4 YL]PHENYL]UREA; 1 (4 BROMOPHENYL) 3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 CHLOROPHENYL) 3 [3 [2 (PYRROLIDIN 1 YL)PYRIMIDIN 4 YL]PHENYL]UREA; 1 (4 CHLOROPHENYL) 3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 CYANOPHENYL) 3 [3 [2 (DIMETHYLAMINO)PYRIMIDIN 4 YL]PHENYL]UREA; 1 (4 CYANOPHENYL) 3 [3 [2 (PYRROLIDIN 1 YL)PYRIMIDIN 4 YL]PHENYL]UREA; 1 (4 CYANOPHENYL) 3 [3 [4 (DIMETHYLAMINO)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 CYANOPHENYL) 3 [3 [4 (PIPERIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 CYANOPHENYL) 3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 FLUOROPHENYL) 3 [3 [2 (PYRROLIDIN 1 YL)PYRIMIDIN 4 YL]PHENYL]UREA; 1 (4 FLUOROPHENYL) 3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 HYDROXYPHENYL) 3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 (4 METHOXYPHENYL) 3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREA; 1 [3 [2 (DIMETHYLAMINO)PYRIMIDIN 4 YL]PHENYL] 3 (3 FLUOROPHENYL)UREA; 1 [3 [2 (DIMETHYLAMINO)PYRIMIDIN 4 YL]PHENYL] 3 (4 FLUOROPHENYL)UREA; 1 [3 [2 (DIMETHYLAMINO)PYRIMIDIN 4 YL]PHENYL] 3 (4 IODOPHENYL)UREA; 1 [3 [4 (AZETIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL] 3 (4 CYANOPHENYL)UREA; 1 [3 [4 (DIMETHYLAMINO)PYRIMIDIN 2 YL]PHENYL] 3 (3 FLUOROPHENYL)UREA; 1 [3 [4 (DIMETHYLAMINO)PYRIMIDIN 2 YL]PHENYL] 3 (4 FLUOROPHENYL)UREA; 1 [3 [4 (DIMETHYLAMINO)PYRIMIDIN 2 YL]PHENYL] 3 (4 IODOPHENYL)UREA; 1 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL] 3 [4 (TRIFLUOROMETHYL)PHENYL]UREA; 4 [3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREIDO]BENZOIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CARBANILAMIDE DERIVATIVE; ETHYL 4 [3 [3 [4 (PYRROLIDIN 1 YL)PYRIMIDIN 2 YL]PHENYL]UREIDO]BENZOATE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA;

ALLOSTERISM; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIGAND BINDING; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS;

ALLOSTERIC REGULATION; ANIMALS; HUMANS; PYRIMIDINES; RECEPTOR, CANNABINOID, CB1; UREA;

EID: 85012123734     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01448     Document Type: Article

References (48)

1. Petrocellis, L. D.; Cascio, M. G.; Marzo, V. D. The endocannabinoid system: a general view and latest additions Br. J. Pharmacol. 2004, 141, 765-774 10.1038/sj.bjp.0705666
2. Howlett, A. C.; Breivogel, C. S.; Childers, S. R.; Deadwyler, S. A.; Hampson, R. E.; Porrino, L. J. Cannabinoid physiology and pharmacology: 30 years of progress Neuropharmacology 2004, 47, 345-358 10.1016/j.neuropharm.2004.07.030
3. Mackie, K. Cannabinoid receptors: where they are and what they do J. Neuroendocrinol. 2008, 20, 10-14 10.1111/j.1365-2826.2008.01671.x
4. Mackie, K.; Lai, Y.; Westenbroek, R.; Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor J. Neurosci. 1995, 15, 6552-6561
5. Mu, J.; Zhuang, S.-Y.; Kirby, M. T.; Hampson, R. E.; Deadwyler, S. A. Cannabinoid receptors differentially modulate potassium a and d currents in hippocampal neurons in culture J. Pharmacol. Exp. Ther. 1999, 291, 893-902
6. Mackie, K.; Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 3825-3829 10.1073/pnas.89.9.3825
7. 2+ channel current Am. J. Physiol.: Heart Circ. Physiol. 1999, 276, H2085-H2093
8. Pacher, P.; Bátkai, S.; Kunos, G. The Endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 2006, 58, 389-462 10.1124/pr.58.3.2
9. Turu, G.; Hunyady, L. Signal transduction of the CB1 cannabinoid receptor J. Mol. Endocrinol. 2010, 44, 75-85 10.1677/JME-08-0190
10. Mackie, K. Cannabinoid receptors as therapeutic targets Annu. Rev. Pharmacol. Toxicol. 2006, 46, 101-122 10.1146/annurev.pharmtox.46.120604.141254
11. Grotenhermen, F.; Müller-Vahl, K. The Therapeutic potential of cannabis and cannabinoids Dtsch. Arztebl. Int. 2012, 109, 495-501
12. Cridge, B. J.; Rosengren, R. J. Critical appraisal of the potential use of cannabinoids in cancer management Cancer Manage. Res. 2013, 5, 301-313 10.2147/CMAR.S36105
13. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery Nat. Rev. Drug Discovery 2002, 1, 198-210 10.1038/nrd746
14. Bridges, T. M.; Lindsley, C. W. G-Protein-coupled receptors: from classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 2008, 3, 530-541 10.1021/cb800116f
15. Burford, N. T.; Clark, M. J.; Wehrman, T. S.; Gerritz, S. W.; Banks, M.; O’Connell, J.; Traynor, J. R.; Alt, A. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 10830-10835 10.1073/pnas.1300393110
16. Price, M. R.; Baillie, G. L.; Thomas, A.; Stevenson, L. A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G. Allosteric modulation of the cannabinoid cb1 receptor Mol. Pharmacol. 2005, 68, 1484-1495 10.1124/mol.105.016162
17. Horswill, J.; Bali, U.; Shaaban, S.; Keily, J.; Jeevaratnam, P.; Babbs, A.; Reynet, C.; Wong Kai In, P. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats Br. J. Pharmacol. 2007, 152, 805-814 10.1038/sj.bjp.0707347
18. Navarro, H. A.; Howard, J. L.; Pollard, G. T.; Carroll, F. Positive allosteric modulation of the human cannabinoid (CB1) receptor by RTI-371, a selective inhibitor of the dopamine transporter Br. J. Pharmacol. 2009, 156, 1178-1184 10.1111/j.1476-5381.2009.00124.x
19. Pamplona, F. A.; Ferreira, J.; Menezes de Lima, O. M.; Duarte, F. S.; Bento, A. F.; Forner, S.; Villarinho, J. G.; Bellocchio, L.; Wotjak, C. T.; Lerner, R.; Monory, K.; Lutz, B.; Canetti, C.; Matias, I.; Calixto, J. B.; Marsicano, G.; Guimaraes, M. Z. P.; Takahashi, R. N. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of cb1 cannabinoid receptor Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 21134-21139 10.1073/pnas.1202906109
20. Ignatowska-Jankowska, B. M.; Baillie, G. L.; Kinsey, S.; Crowe, M.; Ghosh, S.; Owens, R. A.; Damaj, I. M.; Poklis, J.; Wiley, J. L.; Zanda, M.; Zanato, C.; Greig, I. R.; Lichtman, A. H.; Ross, R. A. A cannabinoid cb1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects Neuropsychopharmacology 2015, 40, 2948-2959 10.1038/npp.2015.148
21. Bauer, M.; Chicca, A.; Tamborrini, M.; Eisen, D.; Lerner, R.; Lutz, B.; Poetz, O.; Pluschke, G.; Gertsch, J. Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at cb1 receptors J. Biol. Chem. 2012, 287, 36944-36967 10.1074/jbc.M112.382481
22. Kenakin, T. P. Biased signalling and allosteric machines: new vistas and challenges for drug discovery Br. J. Pharmacol. 2012, 165, 1659-1669 10.1111/j.1476-5381.2011.01749.x
23. Kenakin, T.; Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 2010, 62, 265-304 10.1124/pr.108.000992
24. Jing, L.; Qiu, Y.; Zhang, Y.; Li, J.-X. Effects of the cannabinoid CB1 receptor allosteric modulator Org27569 on reinstatement of cocaine-and methamphetamine-seeking behavior in rats Drug Alcohol Depend. 2014, 143, 251-256 10.1016/j.drugalcdep.2014.08.004
25. German, N.; Decker, A. M.; Gilmour, B. P.; Gay, E. A.; Wiley, J. L.; Thomas, B. F.; Zhang, Y. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl) pyridin-2-yl] phenyl} urea (PSNCBAM-1) J. Med. Chem. 2014, 57, 7758-7769 10.1021/jm501042u
26. Müller, C. E.; Schiedel, A. C.; Baqi, Y. Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development Pharmacol. Ther. 2012, 135, 292-315 10.1016/j.pharmthera.2012.06.002
27. Willard, F. S.; Wootten, D.; Showalter, A. D.; Savage, E. E.; Ficorilli, J.; Farb, T. B.; Bokvist, K.; Alsina-Fernandez, J.; Furness, S. G.; Christopoulos, A.; Sexton, P. M.; Sloop, K. W. Small molecule allosteric modulation of the glucagon-like peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin Mol. Pharmacol. 2012, 82, 1066-1073 10.1124/mol.112.080432
28. Sharma, S.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl) pyrimidine scaffold Bioorg. Med. Chem. Lett. 2008, 18, 4098-4101 10.1016/j.bmcl.2008.05.091
29. B receptor function J. Pharmacol. Exp. Ther. 2003, 307, 322-330 10.1124/jpet.103.053074
30. Urwyler, S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives Pharmacol. Rev. 2011, 63, 59-126 10.1124/pr.109.002501
31. Brown, D. J. The Chemistry of Heterocyclic Compounds, the Pyrimidines; John Wiley & Sons: New York, 2009; Vol. 52; pp 4-6.
32. Fleming, F. F.; Yao, L.; Ravikumar, P.; Funk, L.; Shook, B. C. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore J. Med. Chem. 2010, 53, 7902-7917 10.1021/jm100762r
33. Levinson, N. M.; Boxer, S. G. A conserved water-mediated hydrogen bond network defines bosutinib’s kinase selectivity Nat. Chem. Biol. 2014, 10, 127-132 10.1038/nchembio.1404
34. Kubinyi, H. Hydrogen Bonding: The last mystery in drug design? In Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies; Testa, B.; Waterbeemed, H. V. D.; Folkers, G.; Gay, R., Eds.; Wiley-VCH: Zurich, Switzerland, 2001; pp 513-524.
35. Howlett, A. Cannabinoid receptor signaling. In Cannabinoids; Pertwee, R., Ed.; Springer: Berlin, Heidelberg, 2005; pp 53-79.
36. Derkinderen, P.; Valjent, E.; Toutant, M.; Corvol, J.-C.; Enslen, H.; Ledent, C.; Trzaskos, J.; Caboche, J.; Girault, J.-A. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus J. Neurosci. 2003, 23, 2371-2382
37. i protein-independent ERK1/2 kinase activation J. Biol. Chem. 2012, 287, 12070-12082 10.1074/jbc.M111.316463
38. Khurana, L.; Ali, H. I.; Olszewska, T.; Ahn, K. H.; Damaraju, A.; Kendall, D. A.; Lu, D. Optimization of Chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1) J. Med. Chem. 2014, 57, 3040-3052 10.1021/jm5000112
39. DeWire, S. M.; Violin, J. D. Biased ligands for better cardiovascular drugs dissecting g-protein-coupled receptor pharmacology Circ. Res. 2011, 109, 205-216 10.1161/CIRCRESAHA.110.231308
40. Wisler, J. W.; DeWire, S. M.; Whalen, E. J.; Violin, J. D.; Drake, M. T.; Ahn, S.; Shenoy, S. K.; Lefkowitz, R. J. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 16657-16662 10.1073/pnas.0707936104
41. William, A. D.; Lee, A. C.-H.; Goh, K. C.; Blanchard, S. p.; Poulsen, A.; Teo, E. L.; Nagaraj, H.; Lee, C. P.; Wang, H.; Williams, M.; Sun, E. T.; Hu, C.; Jayaraman, R.; Pasha, M. K.; Ethirajulu, K.; Wood, J. M.; Dymock, B. W. Discovery of kinase spectrum selective macrocycle (16 e)-14-methyl-20-oxa-5, 7, 14, 26-tetraazatetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacosa-1 (25), 2 (26), 3, 5, 8 (27), 9, 11, 16, 21, 23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (cdks), janus kinase 2 (jak2), and fms-like tyrosine kinase-3 (flt3) for the treatment of cancer J. Med. Chem. 2012, 55, 169-196 10.1021/jm201112g
42. Streeper, R. T.; Pearson, P. G.; Zhao, Z.; Mizsak, S. A.; Vrbanac, J. J. Synthesis of deuterium labeled 2,4-dipyrrolidinylpyrimidine as a chemical probe for P450 mediated oxidation of tirilazad mesylate J. Labelled Compd. Radiopharm. 1998, 41, 577-584 10.1002/(SICI)1099-1344(199807)41:7<577::AID-JLCR108>3.3.CO;2-E
43. Chi, D. Y.; Lee, B. S.; Jung, Y.; Sirion, U.; Lim, Y. J.; Bae, Y. J.; Kim, H.; Chu, S. Y.; Moon, D. H.; Ryu, J.-S.; Kim, J. S.; Oh, S. J. 2-Arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient. US 8,497,260, 2013.
44. Sekiguchi, Y.; Kanuma, K.; Omodera, K.; Tran, T.-A.; Semple, G.; Kramer, B. A. Pyrimidine derivatives and methods of treatment related to the use thereof. PCT/JP2005/006582, 2005.
45. Lebar, M. D.; Hahn, K. N.; Mutka, T.; Maignan, P.; McClintock, J. B.; Amsler, C. D.; van Olphen, A.; Kyle, D. E.; Baker, B. J. CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs Bioorg. Med. Chem. 2011, 19, 5756-5762 10.1016/j.bmc.2011.08.033
46. Yoshida, K.; Taguchi, M. Reaction of N-substituted cyclic amines with 2, 4-dichloroquinazoline, 2, 4-dichloropyrimidine, and its 5-methyl derivative J. Chem. Soc., Perkin Trans. 1 1992, 919-922 10.1039/p19920000919
47. Chen, C.; Okayama, H. High-efficiency transformation of mammalian cells by plasmid dna Mol. Cell. Biol. 1987, 7, 2745-2752 10.1128/MCB.7.8.2745
48. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 1976, 72, 248-254 10.1016/0003-2697(76)90527-3